Currently, the evolution of HER2-low expression from primary breast cancer to residual breast cancer after neoadjuvant therapy was assessed in a cohort by including the HER2-low category in the characterization of primary and post-neoadjuvant residual tumours. The gene discussed is ERBB2; the disease is breast carcinoma.